17 recruiting, 7 completed, 4 terminated, 4 unknown. 21 Phase 1, 19 Phase 2, 3 Early Phase 1, 2 Not applicable, 1 Phase 3.
Follow Acute Lymphoblastic Leukemia, in Relapse: new trials by email Literature Review of Acute Lymphoblastic Leukemia, in Relapse trials Research Report on Acute Lymphoblastic Leukemia, in Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy - B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 | Recruiting | Beijing GoBroad Hospital | 48 | 2026-03-15 | 2026-03-09 |
| Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL CD19 specific Chimeric Antigen Receptor T Cell - Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed | Early Phase 1 | Not yet recruiting | Nationwide Children's Hospital | 12 | 2025-10-01 | 2025-08-15 |
| HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Ruxolitinib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 26 | 2025-10-01 | 2025-09-16 |
| A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies Autologous CD5 CAR T-cells, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells, Newly matched donor-derived CD5 CAR T-cells - T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 54 | 2025-07-09 | 2025-11-26 |
| Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL MC-1-50 - Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | Chongqing Precision Biotech Co., Ltd | 24 | 2024-11-01 | 2024-10-15 |
| Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). CD19/CD22-CAR T cells - Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-07-10 | 2025-08-06 |
| CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies Autologous CD5 CAR T-cells, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells, Newly matched donor-derived CD5 CAR T-cells - T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 54 | 2024-06-18 | 2026-03-10 |
| CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells） - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 1 | Recruiting | Rong Tao | 48 | 2024-05-31 | 2024-06-06 |
| CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction peripheral blood lymphocytes, CIK cell - B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Not applicable | Recruiting | Beijing GoBroad Hospital | 213 | 2024-05-27 | 2026-02-25 |
| Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients CD19 CAR T-cell, CD22 CAR T cells, hematopoietic stem-cell transplantation - B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Not applicable | Recruiting | Beijing GoBroad Hospital | 353 | 2024-04-12 | 2026-03-10 |
| Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO Acute Lymphoblastic Leukemia, Infections | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 158 | 2024-04-04 | 2024-04-11 | |
| Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia Bortezomib - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 2 | Recruiting | Instituto do Cancer do Estado de São Paulo | 50 | 2024-04-01 | 2025-05-16 |
| Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell - T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 80 | 2024-03-22 | 2025-11-26 |
| Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 60 | 2024-02-14 | 2026-08-31 |
| HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies Trametinib, Dexamethasone, Cyclophosphamide - Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 26 | 2023-11-14 | 2025-09-16 |
| Determining the Mechanisms of Loss of CAR T Cell Persistence Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Not Having Achieved Remission | Recruiting | University College, London | 50 | 2023-10-18 | 2026-08-07 | |
| HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Decitabine, Venetoclax, Navitoclax - Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Withdrawn | Princess Maxima Center for Pediatric Oncology | 2023-10-01 | 2024-06-21 | |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies Venetoclax, Azacitidine, Cytarabine - Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary | Phase 1 | Recruiting | Andrew E. Place, MD | 30 | 2023-03-29 | 2026-03-12 |
| Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ), Nivolumab starting at day -1 - B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 26 | 2023-03-15 | 2024-05-29 |
| Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory | Phase 1 | Recruiting | Nelson Hamerschlak | 30 | 2023-02-07 | 2025-09-25 |
Showing 20 of 37. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (37) · Recurrence (9) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (6) · Burkitt Lymphoma (4) · Leukemia (4) · Lymphoma, Non-Hodgkin (4) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, B-Cell (2) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, B-Cell (2) · Myelodysplastic Syndromes (2) · Virus Diseases (2) · Bacterial Infections (1) · Infections (1)
Hematologic Diseases (37) · Hemic and Lymphatic Diseases (37) · Immune System Diseases (37) · Immunoproliferative Disorders (37) · Lymphatic Diseases (37) · Lymphoproliferative Disorders (37) · Neoplasms (37) · Neoplasms by Histologic Type (37) · Leukemia, Lymphoid (36) · Leukemia (33) · Disease Attributes (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Lymphoma (8) · Infections (5)
Dexamethasone (6) · Cyclophosphamide (5) · Bortezomib (4) · Cytarabine (3) · Doxorubicin (3) · Methotrexate (3) · fludarabine (3) · venetoclax (3) · Dasatinib (2) · Mesna (2) · Vincristine (2) · fludarabine phosphate (2) · ruxolitinib (2) · AZD 6244 (1) · Asparaginase (1)
Beijing GoBroad Hospital (6) · Beijing Boren Hospital (3) · Princess Maxima Center for Pediatric Oncology (3) · St. Jude Children's Research Hospital (3) · Chongqing Precision Biotech Co., Ltd (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · Andrew E. Place, MD (1) · Assistance Publique - Hôpitaux de Paris (1) · Chinese University of Hong Kong (1) · ERYtech Pharma (1) · Essen Biotech (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Fondazione Matilde Tettamanti Menotti De Marchi Onlus (1) · Group for Research in Adult Acute Lymphoblastic Leukemia (1) · Hospital General de Mexico (1)
China (14) · France (6) · United States (6) · Italy (5) · Netherlands (4) · United Kingdom (4) · Belgium (3) · Denmark (3) · Austria (2) · Brazil (2) · Finland (2) · Germany (2) · Ireland (2) · Israel (2) · Norway (2)
Aimee C. Talleur, MD (2) · Michel Zwaan, Prof. Dr. (2) · Paco Bautista, MD PhD (2) · Adolfo Martinez Tovar, PhD (1) · Andrej Lissat, MD, PhD (1) · Andrew E Place, MD, PhD (1) · Chi Kong LI, Professor (1) · Jianfeng Zhou, M.D. Ph.D (1) · Julie-An Talano, MD (1) · Livio Pagano (1) · Margaret Lamb, MD (1) · Michel Zwaan, Prof. dr. (1) · Nelson Hamerschlak, MD, PhH (1)
PMID 28116786, PMID 30957229, PMID 32780725, PMID 35446934, PMID 35622074, PMID 36775248, PMID 37863088, PMID 41671463, PMID 42154791
2016 (1), 2019 (1)